The phase 3 FORTITUDE-101 trial, conducted with the support of Zai Lab, has been evaluating bemarituzumab plus mFOLFOX6 ...

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

The drugmaker's dividend streak is impressive, and the stock is trading at reasonable levels. 10 stocks we like better than ...